"dr-reddys"

Pilot programme to administer from the first batch of 1,50,000 doses of Sputnik V vaccines imported from RDIF

Plan to vaccinate 125 million people in the next 8-12 months across the country

For FY21, the company posted a consolidated net profit of Rs 1,952 crore as against Rs 2,026 crore in 2019-20.

The imported doses of the vaccine are presently priced at Rs 995 (Rs 948 plus 5 per cent GST per dose), with the possibility of a lower price point when local supply begins.

RDIF CEO Kirill Dmitriev in a virtual press conference recently said he expected over 50 million doses of Sputnik V vaccine to be manufactured in India by this summer.

According to the Hyderabad-based company, emergency use will be as per the provisions of the new drug and clinical trials rules, 2019 under the Drugs and Cosmetics Act

Dr Reddy's Laboratories is recalling 10,440 (90-count) and 2,24,710 (500 count) bottles of Atorvastatin Calcium tablets in the US market.

Divi's Labs leads city chart followed by Aurobindo, Hetero and Dr Reddy's while Mukesh, Elon Musk tops India & world respectively

After touching a record intra-day high of 50,526.39, the 30-share BSE benchmark ended at 50,255.75, up 458.03 points or 0.92 per cent.

The bridging phase II and phase III study on 1,600 subjects in India is assessing immunogenicity and safety.

Total revenue from operations stood at Rs 4,929.6 crore for the third quarter, up 12.38 per cent year-on-year

The vaccine supplies for the global market will be produced by RDIF's international partners in India, Brazil, China, South Korea and other countries.

The confirmation is based on the first interim data from the largest randomised, placebo-controlled Phase-III clinical trials in Russia involving 40,000 volunteers

Collaboration will allow Dr Reddy’s to identify and use some of the Biotechnology Industry Research Assistance Council’s clinical trial centres

Says it anticipates all services to be up within 24 hours and do not foresees any major impact on its operations

The company has committed to reduce Scope 1 and 2 greenhouse gas (GHG) emissions by 55 per cent by 2030 from a FY2017-18 base year.

This product demonstrates that the company is actively expanding the breadth of its portfolio with a treatment for a rare disease, said Dr Reddy's Laboratories Chief Executive Officer, North America Generics, Marc Kikuchi